Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...

Nobody has ever contracted HIV or hepatitis from toilet roll, as the viruses don't survive for long outside the body.

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

New Delhi: Indian public health campaigners on Wednesday said they will oppose the patent applications of a promising new but ...

One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...

Standard treatment of babies with HIV typically starts two to three months after birth and continues for decades. This new ...

Drug companies typically only ensure drug access ... industry to grant permission for access while tens of thousands of new HIV infections accrue? In principle, solutions to enable access are ...

2024, 7, 8, 2379-2390) Efavirenz is an important drug for treating HIV infection ... a UMBC bioanalytical chemist and senior author on the new paper. “That formed the basis for investigating ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

The HIV drug which costs around $44,000 for twice-yearly ... Worldwide there are 1.3 million infections every year, with one new HIV infection every 24 seconds. Gilead has several patent ...

MIT researchers have developed a new HIV vaccination method that generates a strong immune response with just two doses, one ...